Organization · Venture Capital
Kerna Ventures
Kerna Ventures is an early-stage venture capital firm based in the United States, focusing on investments in advanced therapeutic platform technologies, particularly in genome engineering and computational biology.
Overview
What Kerna Ventures does
What Kerna Ventures is
Kerna Ventures is an early-stage venture capital firm based in the United States, focusing on investments in advanced therapeutic platform technologies, particularly in genome engineering and computational biology.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2022
- Approximate age
- About 4 years
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find Kerna Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Kerna Ventures as a funder
Investment thesis
Kerna Ventures backs frontier science companies emerging from academic and technical depth, focusing on advanced therapeutic platform technologies.
Focus narrative
Kerna Ventures invests in early-stage companies with ticket sizes ranging from $0.5 million to $5 million. The firm primarily targets sectors including genome engineering, quantum computing, and computational biology, seeking to support startups that are rooted in academic research and have the potential to transform their respective fields.
Value beyond capital
Kerna Ventures provides significant value to its portfolio companies by leveraging its academic connections and expertise in frontier science. The firm offers support in talent acquisition, next-round capital, and market access, along with an AI-powered tracker across scientific literature and regular journal clubs to foster innovation.
Terms and economics
- Typical check
- $500,000–$5,000,000
Focus and fit
- Stages
- Seed · Series A
- Regions
- Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 13
Portfolio context
GenEdit: A UC Berkeley spin-out developing tissue-selective polymeric nanoparticles for genetic material delivery targeting CNS disorders. Axent: A stealth-mode UC Berkeley spin-out focused on stem cell therapies through innovations in 3D cell expansion and differentiation. Nodal Therapeutics: A University of Maryland startup developing a therapy delivery platform for autoimmune diseases. Renewal Bio: A Weizmann Institute spin-out advancing a platform technology for building synthetic embryos for transplantation. Geneditor: A stealth-mode company working on an in vivo gene editing platform using antibody-targeted RNA–LNPs. Pasqal: Specializes in quantum computing for drug design and computational tasks. Proteinea: An IndieBio alum developing AI models for protein engineering, focusing on optimizing complex proteins.
Common questions
What to know about Kerna Ventures
Upseed classifies Kerna Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.